Quarterly ResultAug 6, 2026, 07:34 AM
SAB Biotherapeutics Q2 Net Loss $22.5M; SAFEGUARD Study on Track
AI Summary
SAB Biotherapeutics reported a net loss of $22.5 million for Q2 2026, up from $10.1 million in Q2 2025. The company announced that enrollment for its registrational SAFEGUARD study is on track for completion in Q4 2026, with topline data expected in 2H 2027. Additionally, the PRISE-hATG study received a grant from Breakthrough T1D, and the company extended its operational runway through 2028.
Key Highlights
- Net loss for Q2 2026 was $22.5 million, compared to $10.1 million in Q2 2025.
- Cash, cash equivalents, and investment securities totaled $208.0 million as of June 30, 2026.
- Operational runway extended through 2028, supporting SAFEGUARD and PRISE-hATG studies.
- SAFEGUARD study enrollment remains on track for completion in Q4 2026.
- Topline data from the SAFEGUARD study is expected in 2H 2027.
- PRISE-hATG study awarded a grant from Breakthrough T1D.
- Began construction of a second farm facility to expand Tc-Bovine platform capacity.
- Included in the Russell 3000® and Russell 2000® indexes in June 2026.
Price Impact
More from SABS